The global ophthalmic drugs market size is expected to reach USD 60.3 billion by 2028. The market is expected to expand at a CAGR of 6.4% from 2021 to 2028.
An increase in the prevalence of eye-related disorders, such as presbyopia, macular degeneration, and diabetic retinopathy, is one of the major drivers of the market. According to the American Academy of Ophthalmology, over 2.71 million people in the U.S. were affected by Primary Open-angle Glaucoma (POAG) in 2011, and the number is estimated to reach 7.3 million by 2050.
Moreover, due to COVID-19, it has become increasingly unsafe for individuals to touch their face several times a day, which is a known cause of transmission. Therefore, companies are developing long-acting, hands-free therapies to combat such challenges.
For instance, in April 2020, Ocular Therapeutix, Inc. completed Phase III clinical trial to evaluate the safety and efficacy of DEXTENZA for allergic conjunctivitis. It is a hands-free therapy administered in the office setting as an intracanalicular insert. It is bioresorbable and designed to release the corticosteroid dexamethasone to the ocular surface, lasting 30 days. It is a one-time and long-acting therapy that can be useful during the COVID-19 crisis.
Investors are increasingly funding companies to support the clinical development of novel treatments for eye diseases thereby fueling the market growth. For instance, in February 2019, Oyster Point Pharma, Inc. received USD 93 million series B financing from Invus Opportunities, Flying L Partners, New Enterprise Associates (NEA), Versant Ventures, and Vida Ventures. The company's product candidates include OC-01 and OC-02 in a Phase 2b clinical trial.
In addition, increasing development and approval of new laboratory methods is expected to boost the market growth. For instance, in July 2020, Quest Diagnostics received emergency Use Authorization (EUA) from the U.S. FDA for a laboratory technique that was developed for extracting viral RNA. This new technique was designed to expand the testing capacity of the Covid-19 molecular tests.
Furthermore, key players in the market undertake various strategies to strengthen their product portfolios and offer diverse, technologically advanced, and innovative products. For instance, in September 2019, Alcon introduced iLUX Patient Care Kits to support practices in treating people with dry eyes in the U.S.
Ophthalmic Drug Market Report Highlights
In 2020, anti-VEGF agents dominated the market owing to high preference by ophthalmologists, enhanced tissue penetration, and rapid responsive rates.
Retinal disorders was the fastest-growing disease segment in 2020 owing to an increase in the prevalence of age-related macular degeneration and diabetic retinopathy, technological advancements, and the rising strategic collaborations.
The topical route of administration dominated the market in 2020 due to the high patient compliance, non-invasiveness, and self-administrability.
The eye drops segment is estimated to witness the fastest growth over the forecast period due to impending launches of several ophthalmic solutions and suspensions in the near future and its direct drug delivery mechanism.
North America dominated the market and accounted for the largest revenue share in 2020 owing to the rising consumer awareness, high disease burden, technological advancements, and proactive government measures.
Key Topics Covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary 2.1 Market Outlook 2.2 Segment Outlook 2.3 Competitive Insights